2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5510 Co-occurring myeloid mutations are associated with TKI resistance and transformation in chronic phase CML: A multicenter analysis

Umar Iqbal, MD, MBBS, Akriti G Jain, MD, FACP2, Alieya Abbas3, Jhonsley Frederic, MD4, Mahesh Kumar, MD5, Todd Knepper, PhD6, Jinming Song, MD, PhD7, Ling Zhang, MD8, Rory Shallis, MD9, Andrew T Kuykendall, MD10, Seongseok Yun, MD, PhD11, Samuel Benjamin Reynolds, MD12, Alison Walker, MD13, Jeffrey Lancet, MD14, Rami Komrokji, MD15, David Sallman, MD16, Eric Padron, MD17, Javier Pinilla-Ibarz, MD PhD18, Onyee Chan, MD19, Talha Badar, MD20, Anthony Michael Hunter, MD21, Venkata Preetam Sandeep Kaduluri22, Alexander Joseph Ambinder, MD, MPH23, B. Douglas Smith, MD24, Kendra L. Sweet, MD, MS25, Zhuoer Xie, MD,MS26
1 Moffitt Cancer Center, Tampa, United States
2 Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
3 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, United States
4 Winship Cancer Institute of Emory University, Atlanta, United States
5 Mayo Clinic Comprehensive Cancer Center, Jacksonville, United States
6 Moffitt Cancer Center, Tampa, United States
7 Moffitt Cancer Center, Tampa, United States
8 Moffitt Cancer Center, Tampa, United States
9 Moffitt Cancer Center, Tampa, United States
10 Moffitt Cancer Center, Tampa, United States
11 Moffitt Cancer Center, Tampa, United States
12 Moffitt Cancer Center, Tampa, United States
13 Moffitt Cancer Center, Tampa, United States
14 Moffitt Cancer Center, Tampa, United States
15 Moffitt Cancer Center, Tampa, United States
16 Moffitt Cancer Center, Tampa, United States
17 Moffitt Cancer Center, Tampa, United States
18 Moffitt Cancer Center, Tampa, United States
19 Moffitt Cancer Center, Tampa, United States
20 Mayo Clinic Comprehensive Cancer Center, Jacksonville, United States
21 Winship Cancer Institute of Emory University, Atlanta, United States
22 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, United States
23 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, United States
24 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, United States
25 Moffitt Cancer Center, Tampa, United States
26 Moffitt Cancer Center, Tampa, United States

Background: Although BCR::ABL1 is the defining driver of chronic myeloid leukemia (CML), additional somatic mutations in myeloid-associated genes may contribute to biological heterogeneity and influence response to tyrosine kinase inhibitors (TKIs). We hypothesized that co-occurring myeloid mutations identify a clinically distinct subgroup of patients with chronic phase CML (CML-CP) characterized by inferior molecular response and increased risk of progression to accelerated or blast phase (AP/BP).

 Methods: We retrospectively analyzed patients with CML  who underwent standard next-generation sequencing (NGS) during chronic phase of disease (CP). Patients were classified as myeloid mutation positive (M+) and myeloid mutation negative (M-). Baseline clinical and laboratory characteristics, TKI exposure and discontinuation, molecular responses, and transformation to accelerated or blast phase (AP/BP) were compared. Continuous variables were assessed using the Mann-Whitney U test; categorical variables were assessed using chi-square or Fisher exact tests, as appropriate.

Results: Among  271 patients, 75 (27.7%) had myeloid mutations, including 21 (28%) pts with multiple mutations, for a total of 107 variants. Of these, the most frequent mutations were in the ASXL1 (n=29; 38.7%), DNMT3A (n=12; 16.0%) and TET2 (n=10; 13%) genes with a median VAF of 34.2% (IQR,13-48.3%). The median time from CML diagnosis to NGS testing was 11.5 months (IQR, 0.1–45.3) and did not differ significantly between the M+ and M− cohorts (p=0.907). Age was similar between the M+ and M- cohorts (median, 46.8 vs 51.0 yrs;p=0.320). Myeloid mutations were more common in male than female patients (34.4 % vs. 19.2 %, p=0.005) and among Black than White patients (47.7% vs 23.6%; overall racial distribution, p=0.005).

At CML-CP diagnosis, the  M+ cohort had lower baseline hemoglobin levels than the M- cohort (median, 9.8 vs 11.4 g/dL; p=.005).  WBC and platelet counts, rates of splenomegaly, standard cytogenetics, and IS values were similar between the cohorts. At diagnosis, the prevalence of cardiovascular, pulmonary, renal, hepatic comorbidities and other malignancies did not differ significantly between the M+ and M- cohorts. Median follow-up was 5.6 yrs (IQR 2.6-9.9) overall but was significantly shorter in the M+ than in  M- cohort (3.9 vs 6.9 yrs, p=0.003).

Molecular responses were inferior in the M+ cohort with lower rates of major molecular response (MMR) at 1 year (34.2% vs 55.5%; p=.026), MMR at any time (48% vs 66.8%; p=.004), and MR4 or deeper response at any time (36% vs 53.6%; p=.010). Median time to best response did not differ significantly between the M+ and M- cohorts (2.8 years [IQR, 1.5-6.2] vs 3.1 years [IQR, 1.3-6.2]; p=0.897). Transformation to AP/BP was more frequent in the M+ than M- cohort (17.3% vs 4.1%; p<0.001), as was the detection of ABL1 kinase domain mutations (29.2% vs 11.8%; p<0.001). Treatment-free remission was attempted less frequently in the M+ than M- cohort (2.7% vs 10.2%; p=.042).

The median number of TKIs used(2 [IQR, 1–3] in both; p=0.114)   and agent-specific discontinuation rates , including adverse events and inadequate or lost response were  similar in the M+ and M− cohorts. Ponatinib (38.7% vs 17.9%; P<0.001) and asciminib use (30.7% vs 16%; p=0.009) was more frequent in the M+ cohort.

Finally, mutation-specific subgroup analyses comparing patients with versus without each of the three most common mutations (ASXL1, DNMT3A, and TET2) found no significant differences in MMR achievement, AP/BP transformation, or the number of TKIs used, likely due to small sample size of subgroup analysis

Conclusion: Co-occurring myeloid mutations define a clinically high-risk subgroup of patients with CML-CP characterized by significantly inferior molecular responses, increased reliance on later-generation TKIs, higher rates of ABL1 kinase-domain mutations, and markedly increased progression to AP/BP. These data indicate that additional myeloid lesions capture critical adverse disease biology not accounted for by BCR::ABL1 alone and strongly support incorporation of comprehensive myeloid mutational profiling into baseline risk stratification in CML. Prospective, longitudinal studies integrating serial sequencing, clonal evolution analyses, and functional validation are needed to confirm these findings and elucidate the biological mechanisms driving TKI resistance and disease progression.

Umar Iqbal, MD, MBBS: No relevant conflicts of interest to declare.